A checkout-verified $129/month tirzepatide price — tied for cheapest in our field — attached to the worst quality and experience record on our GLP-1 board.
Embody — the GLP-1 telehealth brand at joinem.co, legally Modern Metabolic Medicine, Inc. — did not exist when we built our October 2026 GLP-1 provider board. It arrived afterward, with a price that forced us to look: compounded tirzepatide at $129 a month, flat at every dose, month to month, no prepayment, free shipping. We confirmed that number ourselves by walking its checkout to the payment step on October 21, 2026.
So we ran the full gauntlet — three blind analyzers, one per dimension, scored against the nine providers already on the board. This is the first entry in our New Challenger series, and it scored 11 out of 30. We are publishing that anyway, because the number is the point: one dimension came back near the top of the field, and two came back ranked tenth of ten by analyzers who never saw each other's work.
Provider site: joinem.co
Affiliate link — we may earn a commission if you sign up, at no extra cost to you.
Every provider goes through three independent analyzers, each owning one dimension and blind to the other two: Value (what you pay at the payment step, what is included, how the billing structure treats you, and what the same money buys elsewhere — not the advertised headline, the billed number), Quality (medical oversight, prescriber credentialing, screening depth, pharmacy sourcing transparency, third-party testing, regulatory record), and User Experience (funnel honesty, consent and billing order, shipping and refill reliability, support access, cancellation friction, and the dispute terms you sign on the way in).
Each analyzer ranks the provider against the field on its dimension alone; we convert rank to points (points = 11 − rank, so #1 earns 10 and #10 earns 1) and sum the three, out of 30. Affiliate relationships are excluded from scoring. Embody's 11/30 was scored on October 21, 2026, before any commercial relationship existed; an affiliate link was added to this page afterward and is disclosed wherever it appears. The score did not move.
Give the price its full due. On October 21, 2026 we walked Embody's tirzepatide funnel to the payment page. The checkout stated "$129/month forever," alongside "Pay 1 month at a time. No contracts, cancel anytime. Medication is included," a checklist claiming "Your price never changes on Embody" and "Cancel anytime, come back anytime," a "Save $220 off every month" line, and shipping at no extra charge. Embody's site adds that the price holds across doses: "Your price remains the same each month as long as you're on the same medication."
That is not a prepay teaser, and the distinction is the whole story. The standard trick in this category is to headline the rate you only get by paying six or twelve months up front — we caught exactly that on another provider this month, a page headlining $239/month tirzepatide that turns out to be roughly $2,800 charged at once.
| Compounded tirzepatide, month-to-month | Price | As of |
|---|---|---|
| Eden — board #1 | $129/month, flat at every dose | Verified on Eden's live site, Oct 4, 2026 |
| Embody (joinem.co) — this challenger | $129/month, flat at every dose | Verified at the payment step, Oct 21, 2026 |
| Sprout Health — board #5 | $199/month month-to-month | Oct 4, 2026 (not funnel-verified) |
| Oak — board #3 | $285/month for a true one-month plan | Oct 4, 2026 |
| Shed — board #2 | $299/month month-to-month | Funnel-walked Oct 21, 2026 |
| Remedy Meds — board #4 | $399/month | Oct 4, 2026 |
| Brand-name Zepbound via LillyDirect | $299 / $399 / $449 per month by dose | Oct 4, 2026 — FDA-approved, refill within 45 days to hold the rate |
Read that table honestly and the #2 ranking is not controversial. At $129 month-to-month, Embody runs $170 under Shed, $156 under Oak, $270 under Remedy Meds, and $170 to $320 under manufacturer-direct brand-name Zepbound — a gap against the middle of our board of roughly $1,900–$3,200 over a year of continuous treatment. No membership fee is claimed, no separate consult charge is advertised, and no prepayment is required to get the rate. The only provider matching it is Eden, at exactly the same $129.
The Quality analyzer placed Embody below every provider on our board — including MEDVi, which sits last on the published October rankings with an FDA warning letter, a partner data breach affecting up to 1.6 million patients, and class-action litigation. Finishing below that takes some doing, so here is the evidence.
Embody's BBB business file records a start date of December 19, 2025 — roughly ten months before this page's verification date. In that time we could not find a single publicly named executive, founder, or medical director anywhere. The legal entity, Modern Metabolic Medicine, Inc., is a Delaware corporation registered at 1811 Silverside Road, Suite 260, Wilmington, DE, a mass registered-agent suite that hides where the business operates. Every incumbent on our board has at least some verifiable operating history behind it; Embody offers none of a public founder, a named medical director, a multi-year history, or a verifiable physical operation.
The same company also trades as SnagRx and RodeoMeds, all three storefronts sharing one BBB file — so the complaint record below is shared, and the operator runs multiple brands selling the same compounded products at different price points. That is the shape of a business that can retire a damaged brand name without retiring the operation behind it.
The live BBB profile we read on October 21, 2026 showed a D+ rating, not accredited, with 256 complaints in the last 12 months — and because BBB records the business starting only in December 2025, all 256 landed in under eleven months. That is roughly 23–25 complaints per month, with one BBB alert on the file. Third-party trackers caught the grade sliding as the count climbed (C− at 199 complaints, D+ at 245, D+ at 256); an August 2026 snapshot of the same shared file recorded an F with 21 complaints, all unanswered, and another site headlined an F with 16 unanswered. The grade swings as the company answers batches. The constant is the volume.
No provider on our board approaches that rate for its age. Eden's BBB F rests on roughly 90–109 complaints across a far larger member base; Remedy Meds' F covers 471 complaints over three years. Embody collected 256 in ten months.
The themes are consistent: repeated shipping delays, near-impossible access to a provider appointment, a fast first order followed by slow refills, refill pricing above the signup rate, and allegations that titrating up is made deliberately difficult.
Embody advertises compounded tirzepatide across the full 2.5 mg to 15 mg range. Customers report that the largest dose actually supplied is 11 mg, with the cap undisclosed anywhere in the funnel — echoed by a BBB complainant alleging deliberate friction on titration. That is not a footnote: the therapeutic ladder runs to 15 mg, and a flat monthly price that becomes unusable at the dose you eventually need is a different offer than the one advertised. We flag this as a customer-reported finding we have not independently confirmed — and the company has not addressed it publicly.
Prescribing runs through OpenLoop Health, a legitimate multi-state network of independently licensed US clinicians, with Embody as the marketing and platform layer on top. Naming the network is a real transparency point; the model behind it is thin. Intake is a questionnaire plus provider review, with "a brief virtual appointment" only "if the provider needs additional information" — async by default, synchronous by exception. We found no required lab work and no individual prescriber credentials published, so you cannot learn whether an MD or an NP signs your prescription before you pay. Most of our board is async too, but this is the weakest end of it: Remedy Meds requires a live video consult before prescribing, and Oak runs an unusually thorough screening questionnaire including family thyroid-cancer history.
Credit where due — Embody names its pharmacies: Red Rock Compounding Pharmacy (St. George, UT), Health Warehouse (Florence, KY), Precision Medicine / Precision Compounding Pharmacy (Bellmore, NY), and Triad Rx (Daphne, AL). That beats Oak, Remedy Meds, and Elevate, none of which name theirs.
Everything after the names is missing. Embody does not state whether any partner is a 503A pharmacy or a 503B outsourcing facility — the distinction that governs what each is legally permitted to make — and we found no certificates of analysis and no third-party testing claims anywhere on the site. That puts it well behind Shed, which names 503A pharmacies and provides COAs on request. One partner also carries history: Triad Rx received an FDA warning letter in 2019, closed out by the FDA in May 2023.
We found no FDA warning letter to Modern Metabolic Medicine, Embody, joinem.co, SnagRx, or RodeoMeds — and no state board actions, lawsuits, FTC or NAD proceedings either. We are not scoring that as clean and you should not read it as clean. The FDA issued roughly 85 warning letters across this category between September 2025 and June 2026, including to Eden and OrderlyMeds on the same day, June 8, 2026. Those pipelines take time to reach a ten-month-old company. An empty enforcement file at this age means the record has not been examined yet, not that it was examined and passed.
There is also a structural reason it may stay thin: Embody's Terms require binding arbitration and waive class actions, suppressing exactly the public paper trail — court filings, consolidated claims — a reviewer would otherwise check.
Second dead-last finish, from a different analyzer who never saw the Quality scorecard. The two agreed without coordinating, which is the clearest signal this exercise produced.
You are charged at checkout before a clinician approves you. Refunds apply only while "medication has not been ordered," a window that in practice closes shortly after intake submission. The Terms are blunter: charges are non-refundable with exactly one exception — a provider-initiated Medical Disqualification, refunding the unused portion. Change your mind, get delayed, or decide the dose cap makes the program useless, and the contract gives you nothing back.
Getting out requires planning ahead. The Terms published October 21, 2026 require that "cancellation requests must be received at least 72 hours prior to your next billing date," and auto-renewal is explicit: recurring charges happen "without additional notice, unless required by law." Miss the window by a day and you own another month of a non-refundable product. An earlier version specified five days' notice, so this provision has already been revised once — read the live version, not ours.
Embody's Trustpilot profile, read October 21, 2026, showed a TrustScore of 3.8 across 10,369 reviews, 10,356 of them posted in the preceding twelve months: 62% five-star, 6% four, 4% three, 4% two, and 24% one-star. That hollow middle is the signature of two separate review populations rather than one. An independent audit of the twenty most recent found every 4–5 star review carrying Trustpilot's "Invited" tag and every 1–2 star review organic — Embody pays for Trustpilot's invitation product. It replies to roughly 99% of negatives within about 24 hours — on the public channel prospects read. Our UX analyzer did not count that as support responsiveness: complainants describe the private support channel and actual provider appointments as nearly impossible to reach.
The praise is real: supportive clinicians and care coaches, an easy portal, fast signup. The complaints are equally consistent: shipping delays, contradictory answers from customer service, and difficulty getting timely help on medication already in transit — while the site advertises "unlimited 24/7 support" and "unlimited appointments" and BBB complainants describe getting an actual provider appointment as almost impossible.
We also searched for organic discussion and found effectively none: no meaningful Reddit threads about Embody or joinem.co across multiple queries. Ten thousand Trustpilot reviews in under a year with near-zero organic chatter is not what word of mouth looks like — it is what invitation-driven review accumulation looks like. Related warning: several "Embody GLP-1 review" articles circulating since July 2026 are explicitly labeled sponsored-content press releases distributed in near-identical form across multiple sites. If a review repeats the company's promotional copy verbatim, it is the company's own release.
The Terms route all claims and disputes to binding arbitration exclusively and state that "class actions and class arbitrations are not permitted," with a 30-day written opt-out. Combined with the no-refund posture and the 72-hour cancellation rule, the UX analyzer called this the most adverse billing-consent package in the field. On availability: the landing page excludes Mississippi and Louisiana, and beyond those two there is no complete published state list — the Terms say only that service is available in "certain states."
Value 9 + Quality 1 + UX 1 = 11 points. Dropped into the October 2026 board, that lands between OrderlyMeds (14) and MEDVi (8) — ninth of ten, above only MEDVi.
Read it correctly. The nine incumbents were not re-scored for this run — their positions come from the October 4, 2026 verification and stand until the next full cycle, when all ten get scored against one refreshed fact base. Totals from two different scoring runs are not perfectly interchangeable, which is why this is a projection and not a rank.
And note what is holding it up. Embody ranked below MEDVi on both Quality and UX yet finishes above it on total points. The Value #2 carries the entire score. Strip the price out and this is the lowest-scoring provider we have evaluated in the category.
Our analyzers never disagreed about the facts — all three worked from the same fact base. The only disagreement was how much a verified low price is worth sitting on top of a record like this one, and the arbiter's answer is: a ninth-place finish. A great price from an operator you cannot evaluate is not a great deal; it is a cheaper bet with a thinner floor.
This is the section we would want read aloud before anyone enters a card number. Both columns below were captured on the same day, October 21, 2026 — the sales page and the contract, live simultaneously, saying different things.
| What Embody's checkout and homepage said | What the Terms & Conditions said |
|---|---|
| "$129/month forever" and "Your price never changes on Embody" (checkout) | "Final charges may vary based on medication and pharmacy selected" — and the Terms separately reserve the right to add provider fees and price differences tied to the prescribed medication or selected pharmacy. |
| "Pay 1 month at a time. No contracts, cancel anytime." (checkout) | Plans are offered as monthly or bundled 3-, 6-, and 12-month commitments, and the customer "agrees to the full commitment period selected." Cancellation applies to renewal of future terms. Not hypothetical: the semaglutide funnel actively sold 3/6/12-month plans when we walked it October 22, 2026 — the 12-month billed as one $828 charge. |
| "Cancel anytime, come back anytime" (checkout) | "Cancellation requests must be received at least 72 hours prior to your next billing date." Auto-renewal charges occur "without additional notice, unless required by law." |
| "No membership or hidden fees" (homepage) | Charges are non-refundable except for a provider-initiated Medical Disqualification, which refunds only the unused portion — even mid-commitment. |
| Advertised tirzepatide up to 15 mg, flat price across doses (site advertising, per third-party reviews) | Silent on dose availability. Customers report an undisclosed cap at 11 mg. |
| Homepage headline: tirzepatide $119/month | Checkout, same day: $129/month. |
When we first read this conflict, a charitable explanation was available: maybe the Terms were stale boilerplate from an earlier commitment-based policy that the "no contracts" checkout had replaced. That reading died on October 22, 2026, when we walked the semaglutide funnel and found a plan page headlined "One Month At A Time — or Lock In Long Term Savings," actively selling 3-, 6-, and 12-month commitment plans — each labeled "flat forever," each anchored to a struck-through $299/mo, the 12-month billed as a single $828 charge. The commitment periods in the Terms are not leftovers; they are live products the same funnel sells today, while its tirzepatide checkout says "no contracts." What remains is how the gap plays out in practice — and "price never changes" is already a claim with a complaint record against it, because BBB complainants specifically report refill pricing above the signup rate, the exact failure mode the marketing promises cannot happen.
What is not a matter of interpretation: if the two documents conflict, the Terms are what you agreed to. Marketing copy is not the contract. And the contract reserves commitment periods, variable final charges, auto-renewal without notice, a 72-hour exit window, near-total non-refundability, and binding arbitration with no class actions. That is the deal, whatever the banner says.
We do not publish or promote any discount, promotion, or code we have not personally confirmed at the payment step. Embody's homepage runs an auto-applied sale banner whose dollar figure and seasonal name have rotated repeatedly through 2026 — precisely the kind of claim that rule exists for. We report no promotional figure as a price on this page — where the banner numbers appear, they appear only as evidence of the gap between the ad and the checkout. The only figure we report is the $129/month tirzepatide price seen at the payment step on October 21, 2026, and even that carries a date for a reason.
This is the comparison that decides the article. Embody's entire case is the price — and at that exact price, the provider holding our #1 slot has a delivered track record behind it.
| Embody (joinem.co) | Eden — board #1 | |
|---|---|---|
| Gauntlet total | 11 / 30 (projected 9th of 10) | 26 points — #1 on the October 2026 board |
| Tirzepatide | $129/month, flat across doses Verified at payment step Oct 21, 2026 |
$129/month, flat at every dose Verified on the live site Oct 4, 2026 |
| Semaglutide | $99/month month-to-month at plan selection; the "$69/mo" banner is a 12-month $828 prepay (cart-verified Oct 22, 2026) | $99/month flat Verified Oct 4, 2026 |
| Billing structure | Month-to-month claimed at checkout; Terms reserve 3/6/12-month commitments and variable final charges | Month-to-month, no membership fee, "lifetime price lock" claimed, cancel anytime |
| Operating history | Ten months. BBB lists a business start date of Dec 19, 2025 | Established platform claiming 200,000+ members |
| Leadership | Anonymous. No named founder, CEO, or medical director; mass registered-agent address | Established platform, 200,000+ members claimed (verified on site Oct 4, 2026); medical leadership not detailed in our fact base |
| Pharmacy sourcing | Four pharmacies named; no 503A/503B designation, no COAs; one partner had a 2019 FDA letter (closed 2023) | Four named PCAB-accredited 503A pharmacies |
| FDA warning letter | None found — but the company is under a year old, so the record is unexamined rather than clean | Yes — June 8, 2026, over manufacturer labeling and a false "FDA-licensed 503(a)" claim. We name it plainly. |
| BBB | D+, not accredited, 256 complaints in under 11 months (~23–25/month), shared across three storefronts | F, roughly 90–109 complaints, mostly unanswered — cancellation friction and refund disputes |
| Trustpilot | 3.8 across 10,369 reviews; 24% one-star; positives solicited, negatives organic | Roughly 4.4–4.5 across 3,400–4,500 reviews |
| Dose ceiling | 15 mg advertised; 11 mg reported cap, undisclosed | Flat pricing at every dose, no reported cap |
| Dispute rights & guarantees | Binding arbitration + class-action waiver, 30-day opt-out | Arbitration terms not examined in our fact base; offers a 15%-in-6-months money-back warranty |
| Our financial interest | Affiliate — we may earn a commission, same as with Eden; the relationship began after the score was locked, and is excluded from scoring | Eden is an affiliate of ours — disclosed here and on our rankings page, and excluded from scoring |
Eden is not spotless and we will not pretend otherwise. It took an FDA warning letter on June 8, 2026 in a category-wide enforcement wave, it carries an F at the BBB over cancellation and refund disputes, and it restructured its pricing three times during 2026 — check the funnel before trusting any number, including ours. We also earn a commission if you sign up with either provider — Eden or Embody, both disclosed, both excluded from scoring. The gap in this table is our honest read, not our wallet talking: the Embody commission did not stop us projecting it ninth of ten.
With all of that on the table, the arithmetic still holds. Same $129, same flat-across-doses structure, same compounded tirzepatide — but one of them has a largely organic review base, a disclosed accredited pharmacy network, a bounded and specific regulatory flaw, and products that demonstrably arrive. The other is ten months old, anonymous, with customers reporting an undisclosed cap below the dose it advertises, and collecting complaints at 23 a month. Eden's problems are documented and finite; Embody's problem is that there is not enough record to know how big its problems are.
Embody's site, if you want to read the terms yourself: joinem.co — the Terms & Conditions are linked in its footer and are the document that governs, whatever the sales page says.
Affiliate link — we may earn a commission if you sign up, at no extra cost to you.
Nine providers, three dimensions, every FDA warning letter and BBB grade named — including the ones belonging to our own affiliates.
View the 2026 GLP-1 Rankings →Everything above compares compounded sellers, and that comparison sits inside a larger risk applying to all of them equally — Embody, Eden, and every other provider on our board.
We say this on every page in this category: if you can get an FDA-approved GLP-1 through insurance or a manufacturer-direct program, that is the better medical choice. Compounded products exist because the approved ones are expensive, not because they are superior. Our insurance coverage guide covers employer plans, the Medicare Bridge demonstration, Medicaid by state, and the appeal tactics that work.
Yes — as a price quoted at a checkout on one specific day. A human on our team walked Embody's tirzepatide funnel to the payment step on October 21, 2026 and the page stated "$129/month forever," billed one month at a time, medication and shipping included, no prepaid commitment. We stand behind that as of that date.
What we cannot verify is forever. The Terms published the same day reserve the right to vary final charges, and BBB complainants report refill pricing above their signup rate. Treat $129 as a verified entry price, not a guaranteed one.
Unclear, and that is the problem. Embody advertises the full 2.5–15 mg range at a flat monthly price, but customers report the largest dose actually supplied is 11 mg, with the cap disclosed nowhere in the funnel, and a BBB complainant alleges deliberate friction on titration. We have not independently confirmed the cap with the company.
If you expect to need 12.5 mg or 15 mg, get written confirmation from support that those doses are available to you before paying — the charge is non-refundable once medication is ordered, so "find out later" is an expensive plan.
Mechanically it is less hostile than the field's worst — OrderlyMeds requires a phone call to cancel — but the timing rule is strict: the Terms as published October 21, 2026 require cancellation at least 72 hours before your next billing date, and auto-renewal charges happen "without additional notice, unless required by law." Miss the window and you own another non-refundable month. An earlier version specified five days, so the provision has already changed once — read the live version, and set a recurring reminder four days before each billing date from day one.
Embody's Terms state that all claims and disputes are "resolved exclusively by binding arbitration" and that "class actions and class arbitrations are not permitted." In plain English: if something goes wrong you cannot sue in court and cannot join other customers with the same problem — you arbitrate alone. There is a 30-day opt-out by written notice, and if you sign up anyway, exercising it in your first month is the highest-value five minutes available to you. The clause also distorts the public record: a clean litigation search against a company whose customers signed away joint filing proves very little.
Not at this age. We found no FDA warning letter to Modern Metabolic Medicine, Embody, joinem.co, SnagRx, or RodeoMeds, and no state board actions, lawsuits, or FTC or NAD proceedings. But the FDA issued roughly 85 warning letters across this category between September 2025 and June 2026, and those investigations take time to reach a ten-month-old company. An empty file here means unexamined, not cleared. Compare Eden's June 8, 2026 letter: a known, bounded, specific flaw. Known flaws are easier to price than unknown ones.
Because the samples are collected differently. Embody pays for Trustpilot's invitation product, and an audit of the twenty most recent reviews found every 4–5 star review tagged "Invited" while every 1–2 star review arrived organically — a solicited sample skews positive by construction. BBB complaints come from people motivated enough to file formally, and there are 256 of them in under eleven months against a D+ rating. Read the one-star reviews, not the score.
This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs with real risks, including serious gastrointestinal effects, gallbladder disease, pancreatitis, and a boxed warning for thyroid C-cell tumors; they are contraindicated in pregnancy and in people with a personal or family history of medullary thyroid carcinoma or MEN-2. Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or manufacturing quality. Nothing on this page is a recommendation to start, stop, or change any medication. Talk to a licensed clinician who knows your full medical history before making any treatment decision, and seek immediate medical attention for severe abdominal pain, persistent vomiting, or signs of an allergic reaction.
Last verified: October 22, 2026. Every price, rating, complaint count, and contract term on this page carries the date we observed it, and all of them can change without notice — Embody's own Terms have already been revised at least once in the period we tracked. The $129/month tirzepatide figure reflects a single checkout session on October 21, 2026; the semaglutide figures reflect a funnel walk to the cart summary on October 22, 2026 ($99/month at plan selection; the "$69/month" plan billed as a single $828 charge) — no payment was completed on either walk. Verify current pricing, dose availability, state availability, and cancellation terms directly with the provider before purchasing.
Scoring note. The 11/30 total is a solo "New Challenger" result produced by three blind analyzers scoring Embody against the nine providers on our October 2026 board. The incumbents were not re-ranked in this exercise; their published scores stand until the next full re-verification cycle, at which point Embody receives an official placement. The 9th-of-10 figure is a projection, stated as such.
Financial disclosure. Embody links on this page are affiliate links — we may earn a commission if you sign up. That relationship began after this evaluation was complete: the gauntlet was scored October 21, 2026, the affiliate link was added afterward, and the 11/30 result did not change. Eden, Oak, Shed, Sprout Health, PeterMD, and MEDVi, which appear on this page by comparison, are also affiliate partners and we may earn a commission from them; Remedy Meds, Elevate Health, and OrderlyMeds are not. Monetization is excluded from scoring — this page projects an affiliate of ours into ninth of ten, and our October 2026 board dropped another to last place. We state this plainly so you can weigh it yourself.